INTRODUCTION
Excessive daytime sleepiness (EDS) is the most common concern for many people suffering from sleep disorder and has progressively moved from an unknown medical condition to a known public health risk. 1 It has been defined by the American Academy of Sleep Medicine 2 as the inability to maintain wakefulness and alertness during the major waking episodes of the day, with sleep occurring unintentionally or at inappropriate times almost daily. Reports of prevalence of EDS in various studies ranges from around 3% in randomly selected drivers to 20% in an elderly cohort, 3 and as high as 22.6% in a study of EDS and risk of occupational injuries in non-shift daytime workers. 4 Hypertension is a pathology associated with high morbidity and mortality rates in the developed and developing world. It is estimated to cause 7.5 million deaths, about 12.8% of the total number of deaths worldwide. 5 Across the WHO regions, the prevalence of raised blood pressure (BP) in adults was highest in Africa, where it was 46% for both sexes. 5 In Sub-Saharan Africa, it is the most frequent cardiovascular risk factor for cardiovascular disease, with a prevalence estimate of 47.5% in a self-selected sub-Saharan urban population in Cameroon. 6 7 An association between EDS and hypertension has been a frequent finding in recent studies. In a 5-year follow-up study of 157 adults by Goldstein et al, 8 patients with more symptoms of EDS had increased casual and sleep BP variability during waking hours.
Strengths and limitations of this study
▪ All participants were interviewed by a trained investigator, ensuring the accuracy of data collected. ▪ The reduced number of men in this study might have underappreciated the effect of gender on excessive daytime sleepiness. ▪ Ambulatory monitoring of blood pressure over 24 h, which is the best method for the evaluation of controlled blood pressure, was not used.
These individuals with increased symptoms of EDS were more likely to be diagnosed with hypertension within the 5-year follow-up period. Likewise, Newman et al 9 reported increased cardiovascular disease (CVD) mortality of 200% for men and 40% for women in patients with EDS. These were also associated with an increase in cardiovascular events. With the evidence of EDS and its relationship with hypertension and CVD, it remains underdiagnosed and undermanaged, especially in sub-Saharan Africa. Adewole et al 10 reported the prevalence of risk of sleep apnoea to be 19% in Nigeria while Mapoure et al 11 reported 3.8% prevalence of EDS in Cameroon. These studies were, however, carried out in the general population, and studies in the cardiovascular and particularly the hypertensive population remain scarce. We therefore aimed in this study to determine the prevalence and determinants of EDS among hypertensive patients.
METHODS

Study design and setting
This was a cross-sectional study conducted at the cardiology outpatient unit of the Douala General Hospital (DGH) from 1st January to 31st July 2013. Douala is a seaside city and the economic capital of Cameroon, hosting many industries. Its population in 2010 was estimated at 2.1 million inhabitants, originating from different regions of the country.
Participants
Patients who presented themselves at the cardiology outpatient unit of the DGH for a routine consultation were included in the study. They were all above 15 years of age, had been diagnosed as hypertensive and were followed-up at the cardiology outpatient unit. Patients were excluded from the study if they were on sedatives, or if they had a past or present history of stroke, heart failure or head trauma.
Data collection
Patients were consecutively invited to participate in the study. Data were obtained from the patients on a questionnaire during an interview administered by a trained investigator. Demographic characteristics, medical history and information on smoking status and alcohol consumption, were collected. Biological parameters (blood uric acid, lipid profile) were extracted from the patients' files. The Epworth sleep questionnaire was administered and the anthropometric data (weight, height, neck circumference, waist circumference) as well as the BP, were measured.
Definitions
The weight (in kg) of the patient was collected with the help of a scale balance ( patient standing at the anatomical position on a scale balance) and the height (in cm) with the help of a stadiometer ( patient standing at the anatomical position in front of the stadiometer). These enabled us to calculate the body mass index (BMI) with the formula weight/(height×height) that classified patients to either being obese (BMI ≥30 kg/m 2 ) or not.
12
Neck circumference was measured using a metre tape at the mid-way point of the neck between mid-cervical spine and mid-anterior neck to 0.5 cm, if palpable, just below the laryngeal prominence. 13 The waist circumference was measured at the narrowest waist level, or if this was not apparent, at the midpoint between the lowest rib and the top of the hip bone (iliac crest). The tape was placed horizontal to the body, not too tight or too loose.
14 BP was measured twice on the upper left arm, after at least 5 min of rest, using a validated automatic BP device (Spengler) and the second BP value was used for analysis. 6 Hypertension was diagnosed if the patient had a systolic (and/or diastolic) BP of 140 (90) mm Hg or higher on two different occasions, or if the patient was on BP lowering medications over the last 15 consecutive days. Controlled BP was defined as systolic BP less than 140 mm Hg and diastolic BP less than 90 mm Hg in patients under BP lowering medications. 6 Participants were considered to have diabetes if they were treated with hypoglycaemic medications (insulin diabetes medications) or if their fasting blood glucose levels reached 126 mg/dL or more. 15 Dyslipidaemia was defined by high total cholesterol (>2.7 g/L), high levels of triglycerides (>1.4 g/L), high levels of low-density lipoprotein (>1.6 g/L) or low levels of high-density lipoprotein cholesterol (<0.29 g/L). 16 Waist circumference >94 cm in men or 80 cm in women was considered to be high. Neck circumference was considered high when it was ≥43 cm. 13 Participants who smoked at least one cigarette per day were classified as current smokers and those who had stopped smoking for more than 3 years were classified as former smokers. Patients were considered snorers when their bed partners or house mates testified to it. Hyperuricaemia was defined by blood uric acid level greater than 70 mg/L. 16 EDS was the outcome variable. It was defined as an Epworth Sleepiness Scale (ESS) score ≥10. The ESS is a scale used to measure sleep propensities in eight different situations of real-life: (1) sitting and reading, (2) watching television, (3) sitting, inactive in a public place, (4) as a passenger in a car for an hour without a break, (5) lying down to rest in the afternoon when circumstances permit, (6) sitting and talking to someone, (7) sitting quietly after a lunch without alcohol and (8) in a car while stopped for a few minutes in traffic. The range of an item-score was 0-3 on the Likert scale: never doze (score=0), slight chance of dozing (score=1), moderate chance of dozing (score=2) and high chance of dozing (score=3). The ESS score is the sum of the eight item scores (range, 0-24); the higher scores indicate being more sleepy. 
were identified using the χ 2 test in the univariate analysis. Significant variables from the χ 2 test were then included in the multivariate logistic regression model for the assessment of the independent effect of individual factors. The ORs and their 95% CIs were reported. A p value of 0.05 was considered statistically significant.
Ethical issue
The study was approved by the National Ethics Committee and oral consent was obtained from each participant before the recruitment.
RESULTS
Participants
Out of 508 patients invited to participate in the study, 470 (92.5%) accepted. As shown in figure 1 , 32 patients were excluded due to the presence of one or more exclusion criteria and 27 questionnaires were further excluded from analysis due to incomplete information; a total of 411 patients were finally included in the study (figure 1).
Baseline characteristics of participants
From 411 participants, females made up the majority with a total of 260 (63.3%). The age of the respondents ranged from 27 to 90 with a mean age of 55.5±9.7 years. The mean BMI was 30±81 kg/m 2 (range 21-48.3). On the contrary, 226 (54.9%) patients were obese and 15 (3.6%) had morbid obesity. The percentage of controlled BP was 22.4% (92 patients). Two hundred and fifty-eight (258) patients had an Epworth Sleeping Score ≥10, giving a prevalence of EDS at 62.8% (95% CI 58 to 67.4). The other characteristics of participants are given in table 1. 
Factors associated with EDS
From the univariate analysis (
DISCUSSION
In this study, we found that more than 6 of 10 hypertensive patients have EDS. This condition was significantly associated with type 2 diabetes, obesity, snoring and uncontrolled BP. EDS was screened in 62.8% of participants. This was similar to the 67.8% prevalence of EDS in hypertensive and obstructive sleep apnoea patients reported by Wang et al 17 in China. It was greater than the 3.8% reported by Mapoure et al 11 in the general population in Cameroon. In a study among middle-aged adults in France, the prevalence of EDS was estimated at 18%. 18 These findings show that EDS in hypertensive patients is high and the marked difference between EDS prevalence in the general population versus hypertensive patients supports the fact that hypertension is a well documented risk factor for developing sleep-related disorders. 19 The factors independently associated with EDS in this study were type 2 diabetes, obesity, snoring and uncontrolled BP. Akintunde et al 19 found an association between snoring and EDS among hypertensive patients. In addition, sleep disorders have been shown to be independently associated with obesity and hypertension. 20 21 In the Wisconsin sleep cohort study, a one SD difference in BMI was associated with a fourfold increase in the prevalence of sleep-disordered breathing. 22 Snoring has been reported as one of the cardinal manifestations of sleep related disorders and is sometimes taken for sleep-disordered breathing itself. 18 Our study shows an independent relationship between EDS and type 2 diabetes. Sleep apnoea, which is a major cause of EDS, has been shown to be associated with insulin resistance and type 2 diabetes. 23 BP control was associated with EDS in this study. Several other studies have reported sleep apnoea syndrome and EDS as being related to resistant hypertension. 24 Impaired sodium handling, sympathetic activation, accelerated arterial stiffening and impaired cardiorenal haemodynamics contribute to drug resistant hypertension development in EDS, and sleep apnoea. 24 Hyperuricaemia was not associated with EDS in our study. However, Verhulst et al 25 reported sleep disordered breathing to be related to increased levels of serum uric acid, independent of abdominal adiposity; a finding that contributed to the mechanisms linking sleep disordered breathing with cardiovascular morbidity.
One strength of this study was the fact that all participants were interviewed by an investigator who ensured that data were accurately collected. We also used multivariate logistic regression analysis to investigate factors associated with EDS. This enabled us to avoid the effects of confounders and to obtain factors independently associated with EDS. However, this study has some limitations: the absence of sleep diagnostic tools in our context prevented us from investigating sleep apnoea itself. Nevertheless, EDS has been reported to be positively associated with obstructive sleep apnoea, 26 thus serving as a surrogate in this study. The male sex might have been underappreciated in the study as 31 of the 38 subjects who did not give their consent were males. Likewise, ambulatory monitoring of BP over 24 h, which is the best method for the evaluation of controlled BP, was not used. Another limitation of this study is that our results cannot be generalised to all hypertensive 
